Cyril Konto

IGI Technologies (United States) — United States

Medicine · Health Sciences

18h-index3.1kcitations49works4.42yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Monoclonal and Polyclonal Antibodies Research(19), CAR-T cell therapy research(17), Multiple Myeloma Research and Treatments(13), Cutaneous Melanoma Detection and Management(9), Melanoma and MAPK Pathways(8)

Publications49 total

554 Pharmacokinetics (PK) and pharmacodynamics (PD) of ISB 2001, a BCMAxCD38xCD3 trispecific antibody, in TRIgnite-1, the first-in-human (FIH) phase 1 study in relapsed/refractory multiple myeloma (RRMM)
Regular and Young Investigator Award Abstracts·2025Open Access
TRIgnite- 1Study, Phase 1, First-in-Human Study of ISB 2001: A BCMAxCD38xCD3-Targeting Trispecific Antibody for Patients with Relapsed/Refractory Multiple Myeloma (RRMM)—Dose Escalation (DE) Results
Clinical Lymphoma Myeloma & Leukemia·2025· 1 cited
Phase 1, first-in-human study of ISB 2001: A BCMAxCD38xCD3-targeting trispecific antibody for patients with relapsed/refractory multiple myeloma (RRMM)—Dose escalation (DE) results.
Journal of Clinical Oncology·2025· 4 cited
Abstract CT147: Pharmacokinetics (PK) and pharmacodynamics (PD) of ISB 2001, a novel BCMAxCD38xCD3 trispecific antibody from the first-in-human (FIH) phase 1 study in relapsed/refractory multiple myeloma patients
Cancer Research·2025
Abstract 3694: Clinical validation of a quantitative systems pharmacology (QSP) model of ISB 2001 used for deriving first in human (FIH) dose and efficient phase 1 dose escalation design in relapsed refractory multiple myeloma (RRMM) patients
Cancer Research·2025· 1 cited
First Results of a Phase 1, First-in-Human, Dose Escalation Study of ISB 2001, a BCMAxCD38xCD3 Targeting Trispecific Antibody in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
Blood·2024· 8 citedOpen Access
ISB 2001: Accelerating Patient Benefits through Quantitative Systems Pharmacology (QSP) Guided First-in-Human (FIH) Starting Dose Selection
Blood·2024Open Access
Dose Escalation of ISB 1442, a Novel CD38 Biparatopic x CD47 Bispecific Antibody, in Patients with Relapsed / Refractory Multiple Myeloma
Blood·2024· 1 citedOpen Access
ISB 2001 trispecific T cell engager shows strong tumor cytotoxicity and overcomes immune escape mechanisms of multiple myeloma cells
Nature Cancer·2024· 29 citedOpen Access
Abstract 1238: ISB 2001, a BCMA and CD38 dual targeting T cell engager, demonstrates superior cytotoxicity relative to teclistamab in the samples of patient relapsing from CD38 and BCMA targeted immunotherapies
Cancer Research·2024
Phase 2b randomized trial of OX40 inhibitor telazorlimab for moderate-to-severe atopic dermatitis
Journal of Allergy and Clinical Immunology Global·2023· 40 citedOpen Access
A Phase 1, First-in-Human, Dose Escalation and Dose-Expansion Study of a BCMAxCD38xCD3 Targeting Trispecific Antibody ISB 2001 in Subjects with Relapsed/Refractory Multiple Myeloma
Blood·2023· 4 cited
Integrated Preclinical Data Analysis of ISB 2001 Enables Optimal Starting Dose Selection for a First-in-Class Trispecific T Cell Engager Phase1 Study in Multiple Myeloma
Blood·2023· 1 citedOpen Access
Dose Escalation of ISB 1342, a Novel CD38xCD3 Bispecific Antibody, in Patients with Relapsed / Refractory Multiple Myeloma (RRMM)
Blood·2023· 9 cited
Initial Dose Escalation of ISB 1442, a Novel CD38 Biparatopic x CD47 Bispecific Antibody, in Patients with Relapsed / Refractory Multiple Myeloma (RRMM)
Blood·2023· 6 citedOpen Access
Abstract 2970: Overcoming mechanisms of escape from treatments for multiple myeloma with ISB 2001, a potential first-in-class trispecific BCMA and CD38 targeted T cell engager
Cancer Research·2023· 1 cited
Preclinical Evaluation of ISB 1442, a First-in-Class CD38 and CD47 Bispecific Antibody Innate Cell Modulator for the Treatment of AML and T-ALL
Blood·2022· 4 cited
ISB 2001, a First-in-Class Trispecific BCMA and CD38 T Cell Engager Designed to Overcome Mechanisms of Escape from Treatments for Multiple Myeloma By Targeting Two Antigens
Blood·2022· 14 cited
Abstract 2903: ISB 1442, a first-in-class CD38 and CD47 bispecific antibody innate cell modulator for the treatment of CD38+ malignancies
Cancer Research·2022
P871: ISB 1442, A FIRST-IN-CLASS CD38 AND CD47 BISPECIFIC ANTIBODY INNATE CELL MODULATOR FOR THE TREATMENT OF CD38 POSITIVE HEMATOLOGICAL MALIGNANCIES
HemaSphere·2022· 1 citedOpen Access
page 1 of 3Next →

Frequent Co-authors

Vinu Menon(16), Lida Pacaud(13), Michele Maio(12), Mario Perro(12), Maria Pihlgren(12), Andrew Garton(11), Célèste Lebbé(10), Alessandro Testori(10), Jedd D. Wolchok(9), Sunitha Gn(9), Paul Lorigan(8), Hanlon Sia(8), Beata Holkova(8), Omid Hamid(7), Paolo A. Ascierto(7), Camille Martinet(7), Eugene Zhukovsky(7), Hang Quach(7), A. Dueymes(6), Girish Gudi(6)